Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Inclusion Criteria: * Be willing to comply with study procedures and visit schedule * Are at least 35 years of age * Female subjects \>65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization * Subjects of childbearing potential must be using an acceptable method of birth control. Female subjects who are considered not of childbearing potential must be: documented surgically sterile, OR postmenopausal. * Have a primary diagnosis of COPD. Diagnosis can be made during the screening process. * Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years). * Have a chest x-ray that is consistent with the diagnosis of COPD and taken \<3 months prior to study start * Able to complete all study questionnaires and logs reliably Exclusion Criteria: * Female subject who is pregnant or lactating * Have participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another investigational drug study * Subject whose schedule or travel prevents the completion of all required visits * Are scheduled for in-patient hospitalization, including elective surgery during the trial * Have life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days * History of asthma or any chronic respiratory disease other than COPD (chronic bronchitis and/or emphysema) * Have clinically significant cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol * Have a history of cancer except non-melanomatous skin cancer * Have a history of lung resection of more than one full lobe * Requires continuous supplemental oxygen therapy. * Has had a change in dose or type of any medications for COPD within 14 days prior to the screening visit * Have a known sensitivity to arformoterol, ipratropium, salmeterol or albuterol or any of the excipients contained in any of these formulations * Have a history of substance abuse or drug abuse within 12 months, or with a positive urine drug screen * Are using any prescription drug for which concomitant beta-agonist administration is contraindicated (e.g., beta-blockers)